Please login to the form below
Moderna
This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.
Moderna CEO makes case for firm’s lofty valuation
mRNA specialist has to convince investors after stocks slide. Moderna CEO Stéphane Bancel took the stage at the JP Morgan Healthcare conference yesterday to give an update on the firm’s ... Three additional candidates are due to reach the phase 2
Latest news
-
After December slump, what’s in store for biotech in 2019?
2018 was a bumper year for biotech investment and particularly IPOs, with 58 new listings crowned by Moderna’s record-breaking $604m offering and an escalation in the number of private ... Moderna is now trading almost 20% down on its debut price, for
-
Moderna files record $500m IPO for RNA pipeline
Could be the largest IPO for a biotech start-up. Moderna Therapeutics, a specialist in messenger RNA-based drugs, has filed a $500m initial public offering (IPO) that would break all ... Moderna’s mRNA technology attempts to turn a patient’s own
-
Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate
RNA drug specialist Moderna also have their own OX40L candidate, mRNA-2416 in early stage trials.
-
AZ makes gene therapy move with 4DMT alliance
It also has a long-running collaboration with Moderna seeking messenger RNA drugs for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology, and is
-
Morning brief: New biotech launched, Merck and Moderna expand collaboration and more
A rapid round up of pharma, biotech and healthcare news. Merck and Moderna expand cancer vaccines work. ... The two companies have now added to their collaboration shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer
More from news
Approximately 5 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up to $312m), Moderna [up to
-
Deal Watch June 2016
Apart from the $200m upfront cash payment to Moderna, there were no other financials disclosed. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).
-
Deal Watch October 2015
Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls
-
Deal Watch table for January 2014
144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.
-
Deal Watch table for October 2013
Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).
More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Tony de Fougerolles joins Evox Therapeutics as CEO
Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
-
Medicxi appoints former GSK chair Moncef Slaoui
Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
-
MIT chief financial officer joins Moderna Therapeutics
US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's
-
PureTech Health appoints chief scientific officer
Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
-
Dr Michael Watson appointed as president of Valera
Moderna's technology, coupled with its goal to deliver transformative medicines to millions of patients, makes this an extraordinary opportunity. ... I am eager and proud to join Valera and work with this outstanding team and Moderna's esteemed
More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.
Featured jobs
-
Associate Director
-
£75, 000-90, 000
- Global Business Development Director – Health Education
-
excellent commission
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Director
-
Competitive Salary Offered
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Account Manager / Account Director
-
Competative
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
